FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796488484> ?p ?o ?g. }

• W2796488484 abstract "e14558 Background: Although many clinical trials of newly developed chemotherapeutic drugs have been conducted, limited studies have focused on gastric cancer patients specifically diagnosed with peritoneal carcinomatosis (PC) without measurable regions. In the current study, we characterized the outcomes of systemic chemotherapy and prognostic factors for patients with gastric cancer PC, particularly in cases without measurable disease. Methods: Clinical data from 211 gastric cancer PC patients (137 without and 74 with measurable disease) subjected to systemic chemotherapy between January 2000 and December 2010 at a single center were reviewed. Results: Median OS rates of gastric cancer PC patients with no measurable disease were significantly longer than those of patients with measurable disease (18.2 vs 12.0 months, p=0.011). In multivariate analysis, poor PS (Hazard ratio (HR) = 2.33, 95% CI, 1.42-3.8, P=0.001), presence of metastatic lymphadenopathy (LAP) (HR=2.23, 95% CI, 1.42-3.5, p=0.002) and high-grade PC (HR=1.82, 95% CI, 1.09-3.04, p=0.025) were associated with significantly decreased OS. Combined with clinical PC grade and measurability of disease, median OS of patients with low-grade PC without measurable disease was 19.6 months (95% CI, 15.5-23.7 months). Median OS rates of 12.6, 13.7 and 6.8 months were estimated in high-grade PC without measurable disease, low-grade PC with measurable disease, and high-grade PC with measurable disease, respectively. Median OS of low-grade PC patients with no measurable disease was significantly higher than that of patients in all other groups (p=0.001, p=0.029 and p<0.001, respectively). Conclusions: Gastric cancer PC is a heterogeneous disease entity. In our study, clinically low-grade PC without measurable disease was associated with better outcomes than other groups following systemic chemotherapy. According to the carcinomatosis grade, specific groups of patients may benefit from systemic chemotherapy. Despite the difficulties of response assessment, further clinical trials for newer treatment strategies and molecular studies focusing on the heterogeneity of gastric cancer PC should be introduced." @default.
• W2796488484 created "2018-04-24" @default.
• W2796488484 creator A5000487712 @default.
• W2796488484 creator A5012148094 @default.
• W2796488484 creator A5014474281 @default.
• W2796488484 creator A5015883180 @default.
• W2796488484 creator A5020992348 @default.
• W2796488484 creator A5023344582 @default.
• W2796488484 creator A5042102327 @default.
• W2796488484 creator A5048033504 @default.
• W2796488484 creator A5054661042 @default.
• W2796488484 creator A5083602196 @default.
• W2796488484 creator A5083661343 @default.
• W2796488484 creator A5088316493 @default.
• W2796488484 date "2012-05-20" @default.
• W2796488484 modified "2023-09-28" @default.
• W2796488484 title "Treatment outcomes of peritoneal carcinomatosis arising from gastric cancer with no measurable disease using systemic chemotherapy." @default.
• W2796488484 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e14558" @default.
• W2796488484 hasPublicationYear "2012" @default.
• W2796488484 type Work @default.
• W2796488484 sameAs 2796488484 @default.
• W2796488484 citedByCount "0" @default.
• W2796488484 crossrefType "journal-article" @default.
• W2796488484 hasAuthorship W2796488484A5000487712 @default.
• W2796488484 hasAuthorship W2796488484A5012148094 @default.
• W2796488484 hasAuthorship W2796488484A5014474281 @default.
• W2796488484 hasAuthorship W2796488484A5015883180 @default.
• W2796488484 hasAuthorship W2796488484A5020992348 @default.
• W2796488484 hasAuthorship W2796488484A5023344582 @default.
• W2796488484 hasAuthorship W2796488484A5042102327 @default.
• W2796488484 hasAuthorship W2796488484A5048033504 @default.
• W2796488484 hasAuthorship W2796488484A5054661042 @default.
• W2796488484 hasAuthorship W2796488484A5083602196 @default.
• W2796488484 hasAuthorship W2796488484A5083661343 @default.
• W2796488484 hasAuthorship W2796488484A5088316493 @default.
• W2796488484 hasConcept C121608353 @default.
• W2796488484 hasConcept C126322002 @default.
• W2796488484 hasConcept C143998085 @default.
• W2796488484 hasConcept C185926286 @default.
• W2796488484 hasConcept C2776694085 @default.
• W2796488484 hasConcept C2779134260 @default.
• W2796488484 hasConcept C2991818862 @default.
• W2796488484 hasConcept C526805850 @default.
• W2796488484 hasConcept C530470458 @default.
• W2796488484 hasConcept C71924100 @default.
• W2796488484 hasConceptScore W2796488484C121608353 @default.
• W2796488484 hasConceptScore W2796488484C126322002 @default.
• W2796488484 hasConceptScore W2796488484C143998085 @default.
• W2796488484 hasConceptScore W2796488484C185926286 @default.
• W2796488484 hasConceptScore W2796488484C2776694085 @default.
• W2796488484 hasConceptScore W2796488484C2779134260 @default.
• W2796488484 hasConceptScore W2796488484C2991818862 @default.
• W2796488484 hasConceptScore W2796488484C526805850 @default.
• W2796488484 hasConceptScore W2796488484C530470458 @default.
• W2796488484 hasConceptScore W2796488484C71924100 @default.
• W2796488484 hasLocation W27964884841 @default.
• W2796488484 hasOpenAccess W2796488484 @default.
• W2796488484 hasPrimaryLocation W27964884841 @default.
• W2796488484 isParatext "false" @default.
• W2796488484 isRetracted "false" @default.
• W2796488484 magId "2796488484" @default.
• W2796488484 workType "article" @default.